The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

The only option left for the doctors was liver transplantation and Anakendu's mother came to her rescue by volunteering to ...

A new study published in the journal of Liver International showed that persons with type 2 diabetes had a threefold ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Sarepta Therapeutics Inc. plummeted after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.

Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from ...